Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO
Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering.
By Angel Adegbesan · Bloomberg
Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering.